Amarillo Bioscience, Inc. enters supply agreements in Taiwan, China and Pakistan for Maxisal(TM)
Amarillo Biosciences, Inc. announces supply agreements with STC International for the territories of China and Taiwan and with Majsons Corporation for the territory of Pakistan.
Maxisal(TM), a patented dietary supplement, is the trade name for pharmaceutical grade anhydrous crystalline maltose, which has been found to relieve complaints of dry mouth, enhance salivary function, and promote oral comfort. Amarillo Biosciences, Inc. is the exclusive worldwide (outside Japan) supplier of Maxisal(TM) for the dry mouth market.
Dr. Joseph M. Cummins, President and CEO of Amarillo Biosciences, Inc. said, "We are very pleased that Maxisal(TM) will be sold by our new distributors in their respective territories. Researchers estimate that at least 20% of the population over 50 years of age suffer from persistent complaints of dry mouth. The number of people with dry mouth is even greater if you include people who suffer from autoimmune diseases or take one of the many prescription medications that cause dry mouth." Dr. Cummins concluded, "Our innovative, new product will enable us to continue to take advantage of the many growth opportunities in the biotechnology market. We believe this dry mouth market is poised for significant growth."
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
